Ten Years of Experience and Lessons Learned by DNDi

[January,  2014]

To mark its 10 year anniversary, DNDi has issued a report that explores the lessons learned from a decade of research and development (R&D) of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model.

 
DNDi Model PaperAn Innovative Approach to R&D for Neglected Patients:
Ten Years of Experience and Lessons Learned by DNDi

This report provides elements to stimulate current discussions on the way forward for sustainable mechanisms to provide health tools for developing countries.

Read the Report
Facts & Figures

 
Costs
DNDi’s cost of development ranges from EUR 6-20 million for an improved treatment, and EUR 30-40 million for a new chemical entity. However, the usual attrition in the field of R&D for infectious diseases, and the inherent risk of failure, should be taken into account, bringing the cost range of an improved treatment to EUR 10-40 million, and EUR 100-150 million for a new chemical entity.